Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H6N2O3 |
Molecular Weight | 190.1555 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C2=C1N=CC=C2)[N+]([O-])=O
InChI
InChIKey=RJIWZDNTCBHXAL-UHFFFAOYSA-N
InChI=1S/C9H6N2O3/c12-8-4-3-7(11(13)14)6-2-1-5-10-9(6)8/h1-5,12H
Nitroxoline (8-hydroxy-5-nitroquinoline) has been used since 1962 in the treatment of urinary tract infections especially those due to gram negative bacilli (E. coli). Nitroxoline is active against
most Gram-negative and –positive uropathogenic bacteria, against mycoplasmas (M. hominis, Ureaplasma
urealyticum) and human pathogenic Candida spp. The mode of antibacterial and antifungal action is
based on the ability of nitroxoline to chelate with various
metallic bivalent cations. Nitroxoline is a fluorquinolone that is active against bacterial gyrases. This drug may also have antitumor activity by inhibition of type 2 methionine aminopeptidase (MetAP2) protein which is involved in angiogenesis. Nitroxoline induces apoptosis and inhibits glioma growth in vivo and in vitro. Due to the excellent anticancer activity and its well-known safety profile and pharmacokinetic properties, nitroxoline has been approved to enter into a phase II clinical trial in China for non-muscle invasive bladder cancer treatment
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3922 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24376907 |
55.0 nM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24088053 |
1.0 µM [Ki] | ||
Target ID: CHEMBL4072 |
271.8 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Nibiol Approved UseUrinary antibacterial and antifungal recommended in the treatment of urinary tract infection without fever. Launch Date1961 |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Is nitroxoline an allergen?]. | 2002 Mar-Apr |
|
Thermodynamic investigations of nitroxoline sublimation by simultaneous DSC-FTIR method and isothermal TG analysis. | 2010 Jan |
|
Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and related compounds. | 2011 Aug 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25427651
Curator's Comment: 2 tablets 3 times daily before meals for 10 days. Each coated tablet contains: Nitroxoline 100 mg. http://www.sedico.net/English/products/webpages/Nibiol/Nibiol_e.htm
Nitroxoline was mainly
administered for treatment of uncomplicated and complicated
UTI as well as for prophylaxis of recurrent UTI
with daily dosages mostly between 300 and 900 mg. The
treatment duration varied mainly between 3 and 10 days
depending on the indication.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25427651
The rate of susceptibility of E. coli
at a MIC of nitroxoline of ≤8 mg/l is practically
100% and has not changed over the years as shown by
a recent in vitro study with 499 strains from patients
with community acquired UTI showing MIC50- and
MIC90-values of 2 mg/l and 4 mg/l, respectively. For other uropathogens, such as K. pneumonia, P.
mirabilis. P. vulgaris, M. morganii, and S. saprophyticus
the MIC50- and MIC90-values were between 4–8/
4–8 mg/l with highest MIC of 8 mg/l.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01XX07
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
||
|
WHO-ATC |
J01XX07
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
A8M33244M6
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
67121
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
DB01422
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
DTXSID4046284
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
100000084124
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
19910
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
NITROXOLINE
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
C005308
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
4008-48-4
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
31901
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | RxNorm | ||
|
74947
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
m8012
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB09331MIG
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
1833
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL1454910
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
1954
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
223-662-4
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY | |||
|
C72634
Created by
admin on Fri Dec 15 15:04:10 GMT 2023 , Edited by admin on Fri Dec 15 15:04:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY